KYORIN PharmaceuticalKYORIN Pharmaceutical Co., Ltd.4569東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP
Out of every ¥100 of sales, about ¥3 is left as operating profit. Revenue changed -2.9% from the prior year, operating profit -71.6%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 3.7% | 0.61× | 2.3% | 1.43× | 3.3% |
| 2023 | 4.2% | 0.65× | 2.7% | 1.43× | 3.9% |
| 2024 | 4.6% | 0.68× | 3.1% | 1.43× | 4.4% |
| 2025 | 7.0% | 0.70× | 4.9% | 1.45× | 7.1% |
| 2026 | 2.7% | 0.65× | 1.8% | 1.49× | 2.6% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 105,534 | 113,270 | 119,532 | 130,087 | 126,257 |
| Cost of revenue | 56,093 | 63,102 | 67,904 | 70,551 | 74,634 |
| Gross profit | 49,441 | 50,167 | 51,628 | 59,535 | 51,622 |
| SG&A | 44,433 | 45,043 | 45,394 | 46,967 | 48,055 |
| Operating income | 5,007 | 5,123 | 6,234 | 12,567 | 3,567 |
| Pretax income | 5,216 | 6,906 | 7,239 | 12,770 | 4,451 |
| Income tax | 1,284 | 2,182 | 1,764 | 3,684 | 1,002 |
| Net income attributable to owners | 3,932 | 4,723 | 5,475 | 9,086 | 3,448 |
| Operating margin | 4.7% | 4.5% | 5.2% | 9.7% | 2.8% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥26.3B | ¥18.8B | ¥13.9B | ¥15B | ¥11.8B |
| Total assets | ¥171.9B | ¥176B | ¥177.6B | ¥193.6B | ¥195.5B |
| Net assets | ¥124.5B | ¥125.5B | ¥130.7B | ¥136.3B | ¥142.4B |
| Share capital | ¥700M | ¥700M | ¥700M | ¥700M | ¥700M |
| Property, plant and equipment | ¥24.3B | ¥25.8B | ¥28.9B | ¥30.3B | ¥30.5B |
| Intangible assets excluding goodwill | ¥3.29B | ¥5.39B | ¥5.09B | ¥4.76B | ¥4.08B |
| Investment securities | ¥25.7B | ¥23B | ¥22.1B | ¥20B | ¥18.9B |
| Current assets | ¥116.4B | ¥119B | ¥119.2B | ¥136.1B | ¥135.1B |
| Current liabilities | ¥32.2B | ¥35B | ¥45.5B | ¥35.1B | ¥29.4B |
| Trade payables | ¥10.9B | ¥13.8B | ¥14.3B | ¥15.5B | ¥14.4B |
| Short-term borrowings | ¥10.3B | ¥10.3B | ¥10.1B | ¥7.4B | ¥2.6B |
| Long-term borrowings | ¥10.8B | ¥10.6B | ¥435M | ¥20.2B | ¥20.4B |
| Total liabilities | ¥47.4B | ¥50.6B | ¥46.9B | ¥57.3B | ¥53B |
| Equity attributable to owners of parent | ¥120.5B | ¥122.2B | ¥124.8B | ¥130.9B | ¥131.1B |
| Retained earnings | ¥132.7B | ¥134.4B | ¥136.7B | ¥142.8B | ¥131.5B |
| Treasury stock | -¥17.7B | -¥17.7B | -¥17.4B | -¥17.3B | -¥5.93B |
EDINET (FSA Japan)
有価証券報告書－第68期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第67期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第66期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第65期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第64期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第63期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 50 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.